CIBRA Capital Doubles Down on Amicus Therapeutics Merger Arbitrage Play

CIBRA Capital has made a significant bet on the completion of BioMarin Pharmaceutical's acquisition of Amicus Therapeutics ($FOLD), dramatically increasing its position in the gene therapy company during the first quarter of 2026. The hedge fund accumulated 1.48 million additional shares worth approximately $21.17 million, elevating Amicus to its largest holding at 11.78% of assets under management. The investment represents a classic merger arbitrage strategy, capitalizing on the gap between the current market price and BioMarin's agreed-upon acquisition price of $14.50 per share, offering potential profits of approximately $0.20 per share if the deal closes as structured.

The Merger Arbitrage Opportunity

CIBRA Capital's substantial position in Amicus Therapeutics reflects confidence in the likelihood of deal completion, despite market pricing that leaves room for profit. Merger arbitrage—a strategy that profits from the spread between a company's current trading price and its acquisition price—carries inherent execution risk. The $0.20 per share spread suggests the market is pricing in some probability of deal failure or renegotiation, creating the profit opportunity that attracted CIBRA Capital's significant capital deployment.

The hedge fund's decision to make Amicus its largest position indicates a high conviction thesis. By concentrating 11.78% of AUM in a single arbitrage opportunity, CIBRA Capital is signaling that management believes the acquisition by BioMarin faces minimal regulatory or financing obstacles. The biotech sector has been subject to increased antitrust scrutiny in recent years, particularly for deals involving complementary therapies or overlapping market positions. However, gene therapy acquisitions have historically faced less regulatory resistance than deals in more consolidated therapeutic areas.

Key metrics of the investment:

• Position size: 1.48 million shares acquired in Q1 2026
• Capital deployed: $21.17 million
• Percentage of fund: 11.78% of assets under management
• Deal price: $14.50 per share
• Estimated profit per share: $0.20 (at current spreads)
• Acquirer: BioMarin Pharmaceutical ($BMRN)

Market Context and Strategic Rationale

The BioMarin-Amicus combination makes strategic sense within the broader biotechnology landscape. BioMarin is a leader in rare genetic disorders and metabolic diseases, while Amicus specializes in lysosomal storage disorders and other rare genetic conditions. The acquisition would consolidate expertise and product portfolios within the gene therapy and rare disease spaces, eliminating potential competition and creating operational synergies.

Amicus Therapeutics operates in a highly specialized market where scale, research capabilities, and patient networks provide significant competitive advantages. The company's pipeline includes treatments for rare genetic disorders—precisely the therapeutic area where BioMarin has built its reputation and commercial infrastructure. The strategic rationale suggests BioMarin sees long-term value in integrating Amicus's programs and technology platform.

From a regulatory perspective, the combination of two specialized rare disease companies appears less likely to trigger serious antitrust concerns compared to consolidation among larger, more diversified pharmaceutical manufacturers. The FDA has generally been supportive of consolidation in rare disease areas, where companies serve patient populations too small to support multiple competitors effectively.

The arbitrage spread itself provides useful context. CIBRA Capital's investment thesis rests on the assumption that current market pricing (which implies the $0.20 spread) underestimates deal probability. This could reflect:

• General market skepticism about biotech M&A in a higher-interest-rate environment
• Typical risk premium for potential deal contingencies
• Thin trading liquidity in Amicus shares
• Broader sector volatility affecting rare disease companies

Investor Implications and Forward-Looking Considerations

For Amicus Therapeutics shareholders, CIBRA Capital's substantial new position provides some reassurance about deal certainty, particularly given the fund's reputation and experience in merger arbitrage strategies. Arbitrage funds typically conduct extensive due diligence before making concentrated bets, assessing both deal mechanics and potential regulatory hurdles. The fund's willingness to deploy $21.17 million and make this its largest position suggests management has confidence in successful deal completion.

However, investors should recognize that 11.78% concentration in a single arbitrage position represents meaningful risk for CIBRA Capital's investors. If deal contingencies emerge—whether regulatory, financing-related, or stemming from due diligence issues—the fund could face substantial losses. Merger arbitrage returns are typically modest (0.20 per share represents approximately 1.4% annualized return assuming rapid deal completion), requiring high certainty to justify concentration.

The broader biotech sector context matters considerably. Higher interest rates and tighter credit markets have affected M&A activity across healthcare. However, BioMarin has the financial capacity and strategic motivation to complete this acquisition, and the deal appears to lack obvious antitrust red flags that would trigger prolonged regulatory review.

For BioMarin shareholders ($BMRN), the acquisition represents a deliberate diversification strategy into adjacent rare disease markets. The deal appears sized to be financially manageable—$21.17 million represents the merger arbitrage spread, suggesting the total deal value is reasonable relative to BioMarin's market capitalization and balance sheet.

Conclusion

CIBRA Capital's transformation of Amicus Therapeutics into its largest position represents a high-conviction merger arbitrage bet. The fund's concentration of 11.78% of AUM in this single opportunity reflects management's assessment that the BioMarin acquisition at $14.50 per share will close successfully, delivering the estimated $0.20 per share arbitrage profit. While the strategic logic of the combination appears sound and regulatory risks seem manageable, the significant position concentration carries execution risk. Investors watching the deal's progress should monitor regulatory timelines, financing confirmations, and any emerging issues during the integration planning process. The deal's successful completion would validate CIBRA Capital's thesis about biotech M&A opportunity in the current market environment.